$58M Merger: Chain Bridge I Acquires Cannabinoid Medicines Innovator, Eyes Nasdaq Listing
$58M Merger: Chain Bridge I Acquires Cannabinoid Medicines Innovator, Eyes Nasdaq Listing
$5800萬美元併購：Chain Bridge I收購大麻類藥物創新公司，計劃上市納斯達克
Chain Bridge I (NASDAQ:CBRG) announced on Monday the acquisition of Phytanix Bio, a pharmaceutical company specializing in the development of therapeutics based on cannabinoid and cannabinoid-like molecules. The transaction, valued at $58 million, also includes the assumption of preferred stock and short-term debt, which will convert to preferred stock upon the deal's closure, slated for the fourth quarter of 2024.
Chain Bridge I（納斯達克：CBRG）於星期一宣佈，收購專門從事以大麻素和類大麻素分子爲基礎的治療方案開發的藥品公司Phytanix Bio。這筆交易價值$5800萬，還包括優先股和短期債務的承擔，將在交易的結束時轉換爲優先股，預計於2024年第四季度結束。
Phytanix Bio's Strategic Acquisition Overview
Phytanix Bio的戰略收購概述
Phytanix Bio, a company founded by former GW Pharmaceuticals leaders, holds exclusive intellectual property that has been central to the creation of FDA-approved cannabinoid-based medicines like Sativex and Epidiolex. With...
Phytanix Bio是由前GW Pharmaceutical...
登入免費觀看全文
登入/註冊